What the FDA labels say about taking them together
Everolimus and lisinopril
Lisinopril's FDA label of January 2, 2025 names everolimus in its drug interactions section; everolimus's label does not name lisinopril itself but warns about its class (ACE inhibitors). The lisinopril label: “7.7 mTOR Inhibitors Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the lisinopril FDA label on DailyMed (effective January 2, 2025, Upsher-Smith Laboratories, LLC).
What does the everolimus label say about lisinopril?
Everolimus's label does not name lisinopril itself; it warns about its class (ACE inhibitors):
Everolimus label, drug interactionsUse of Angiotensin Converting Enzyme (ACE) Inhibitors Patients taking concomitant ACE inhibitors with AFINITOR/AFINITOR DISPERZ may be at increased risk for angioedema.
Everolimus label, drug interactionsAvoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)].
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the lisinopril label say about everolimus?
Lisinopril label, drug interactions7.7 mTOR Inhibitor s Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. [ see Warnings and Precautions (5.2) ]
Lisinopril label, warnings and precautionsPatients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. [see Drug Interactions (7.7 , 7.8)].
Source: FDA drug label (Qbrelis, NDA208401), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set 9f6e4e57-a489-4b36-b093-b93865d3717c), via openFDA
Source: FDA drug label (Zestril), NDA019777 (Twi Pharms), as published by Upsher-Smith Laboratories, LLC, effective January 2, 2025 (SPL set 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Lisinopril | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | High blood pressure, Heart attack and coronary artery disease, Heart failure |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $0.0254 per tablet 20 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once